[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fylIexqubn2K2CVXxxY6dtkgP0rqC7Bw4DoNQ9tx180s":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":35,"phaseBuckets":61,"rows":68},"Steno Diabetes Center Copenhagen",[4],109,false,23,5,27371,9,69,[14,17,20,23,26,28,30,33],{"name":15,"count":16},"Type 1 Diabetes",22,{"name":18,"count":19},"Diabetes Mellitus, Type 1",14,{"name":21,"count":22},"Type 2 Diabetes",11,{"name":24,"count":25},"Hypoglycemia",10,{"name":27,"count":25},"Diabetes Mellitus, Type 2",{"name":29,"count":9},"Diabetes",{"name":31,"count":32},"Obesity",4,{"name":34,"count":32},"Non-Alcoholic Fatty Liver Disease",[36,41,46,51,56],{"nctId":37,"briefTitle":38,"date":39,"intervention":40},"NCT06954090","Urinary Proteomics to Guide Early Intervention to Prevent Complications in Type 2 Diabetes - a Feasibility Study","2026-11-30","Semaglutide, 1.34 mg\u002FmL",{"nctId":42,"briefTitle":43,"date":44,"intervention":45},"NCT06532461","A Trial of Three- and Seven-days Insulin Infusions Set","2026-12-31","Novorapid",{"nctId":47,"briefTitle":48,"date":49,"intervention":50},"NCT06147232","Prevention of Chronic Kidney Disease(CDK) Progression in Type 1 Diabetes With Long Term Use of Sodium-Glucose-coTransporter Inhibitors Avoiding Kidney hypOxia","2027-05","Sotagliflozin",{"nctId":52,"briefTitle":53,"date":54,"intervention":55},"NCT07427251","The Postprandial Hypo-Avoid Study","2027-05-01","Low-Dose Glucagon",{"nctId":57,"briefTitle":58,"date":59,"intervention":60},"NCT06082063","Multifactorial Intervention to Reduce Cardiovascular Disease in Type 1 Diabetes","2029-07-01","Aspirin",[62,63,64,65,66,67],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[69,111,142,173,196,224,242,260,280,298,359,402,437,459,486,512,537,560,578,596,614,632,650,678,696,714,740,758,782,806,827,860,885,911,953,984,1010,1038,1066,1092,1117,1143,1161,1179],{"intervention":70,"totalTrials":71,"cells":72},"Finerenone",2,{"EARLY_PHASE1":73,"PHASE1":76,"PHASE2":78,"PHASE3":80,"PHASE4":94,"NA":109},{"trials":74,"activeCount":75},[],0,{"trials":77,"activeCount":75},[],{"trials":79,"activeCount":75},[],{"trials":81,"activeCount":93,"soonestReadout":59},[82],{"nctId":57,"briefTitle":58,"status":83,"phases":84,"primaryCompletion":59,"completion":59,"start":85,"enrollment":86,"conditions":87,"interventions":91},"RECRUITING",[65],"2024-07-01",2000,[88,89,15,90],"Cardiovascular Diseases","Heart Failure","Kidney Failure",[60,92,50,70],"Semaglutide",1,{"trials":95,"activeCount":93,"soonestReadout":39},[96],{"nctId":37,"briefTitle":38,"status":97,"phases":98,"primaryCompletion":39,"completion":99,"start":100,"enrollment":101,"conditions":102,"interventions":106},"ENROLLING_BY_INVITATION",[66],"2027-05-31","2025-11-20",50,[103,104,105],"Type 2 DM","Type 2 DM \u002FDiabetic Nephropathy","Albuminuria",[40,107,108],"Finerenone Oral","Dapagliflozin",{"trials":110,"activeCount":75},[],{"intervention":108,"totalTrials":71,"cells":112},{"EARLY_PHASE1":113,"PHASE1":115,"PHASE2":117,"PHASE3":132,"PHASE4":134,"NA":140},{"trials":114,"activeCount":75},[],{"trials":116,"activeCount":75},[],{"trials":118,"activeCount":75},[119],{"nctId":120,"briefTitle":121,"status":122,"phases":123,"primaryCompletion":124,"completion":125,"start":126,"enrollment":127,"conditions":128,"interventions":130},"NCT02695810","The PRE-D Trial: Effect of Dapagliflozin, Metformin and Physical Activity in Pre-diabetes","COMPLETED",[64],"2018-09-20","2019-01-13","2016-02-24",120,[129,31],"Prediabetic State",[108,131],"Metformin",{"trials":133,"activeCount":75},[],{"trials":135,"activeCount":93,"soonestReadout":39},[136],{"nctId":37,"briefTitle":38,"status":97,"phases":137,"primaryCompletion":39,"completion":99,"start":100,"enrollment":101,"conditions":138,"interventions":139},[66],[103,104,105],[40,107,108],{"trials":141,"activeCount":75},[],{"intervention":40,"totalTrials":71,"cells":143},{"EARLY_PHASE1":144,"PHASE1":146,"PHASE2":148,"PHASE3":150,"PHASE4":152,"NA":171},{"trials":145,"activeCount":75},[],{"trials":147,"activeCount":75},[],{"trials":149,"activeCount":75},[],{"trials":151,"activeCount":75},[],{"trials":153,"activeCount":93,"soonestReadout":39},[154,167],{"nctId":155,"briefTitle":156,"status":157,"phases":158,"primaryCompletion":159,"completion":160,"start":161,"enrollment":162,"conditions":163,"interventions":165},"NCT04061200","Renal Effects of Treatment With Empagliflozin Alone or in Combination With Semaglutide in Patients With Type 2 Diabetes and Albuminuria","UNKNOWN",[66],"2021-07-01","2021-08-01","2019-11-01",80,[164],"Type 2 Diabetes With Renal Manifestations",[40,166],"Empagliflozin 25 MG",{"nctId":37,"briefTitle":38,"status":97,"phases":168,"primaryCompletion":39,"completion":99,"start":100,"enrollment":101,"conditions":169,"interventions":170},[66],[103,104,105],[40,107,108],{"trials":172,"activeCount":75},[],{"intervention":55,"totalTrials":93,"cells":174},{"EARLY_PHASE1":175,"PHASE1":177,"PHASE2":179,"PHASE3":181,"PHASE4":183,"NA":194},{"trials":176,"activeCount":75},[],{"trials":178,"activeCount":75},[],{"trials":180,"activeCount":75},[],{"trials":182,"activeCount":75},[],{"trials":184,"activeCount":93,"soonestReadout":54},[185],{"nctId":52,"briefTitle":53,"status":186,"phases":187,"primaryCompletion":54,"completion":188,"start":189,"enrollment":190,"conditions":191,"interventions":193},"NOT_YET_RECRUITING",[66],"2028-05-01","2026-03-15",18,[192],"Type 1 Diabetes Mellitus",[55],{"trials":195,"activeCount":75},[],{"intervention":50,"totalTrials":71,"cells":197},{"EARLY_PHASE1":198,"PHASE1":200,"PHASE2":202,"PHASE3":214,"PHASE4":220,"NA":222},{"trials":199,"activeCount":75},[],{"trials":201,"activeCount":75},[],{"trials":203,"activeCount":93,"soonestReadout":49},[204],{"nctId":47,"briefTitle":48,"status":186,"phases":205,"primaryCompletion":49,"completion":49,"start":206,"enrollment":12,"conditions":207,"interventions":213},[64],"2025-02",[208,209,18,105,210,211,212],"Nephropathy","Diabetic Nephropathies","Diabetic Complications Renal","Diabetic Complications Cardiovascular","Hypoxia",[50],{"trials":215,"activeCount":93,"soonestReadout":59},[216],{"nctId":57,"briefTitle":58,"status":83,"phases":217,"primaryCompletion":59,"completion":59,"start":85,"enrollment":86,"conditions":218,"interventions":219},[65],[88,89,15,90],[60,92,50,70],{"trials":221,"activeCount":75},[],{"trials":223,"activeCount":75},[],{"intervention":60,"totalTrials":93,"cells":225},{"EARLY_PHASE1":226,"PHASE1":228,"PHASE2":230,"PHASE3":232,"PHASE4":238,"NA":240},{"trials":227,"activeCount":75},[],{"trials":229,"activeCount":75},[],{"trials":231,"activeCount":75},[],{"trials":233,"activeCount":93,"soonestReadout":59},[234],{"nctId":57,"briefTitle":58,"status":83,"phases":235,"primaryCompletion":59,"completion":59,"start":85,"enrollment":86,"conditions":236,"interventions":237},[65],[88,89,15,90],[60,92,50,70],{"trials":239,"activeCount":75},[],{"trials":241,"activeCount":75},[],{"intervention":92,"totalTrials":93,"cells":243},{"EARLY_PHASE1":244,"PHASE1":246,"PHASE2":248,"PHASE3":250,"PHASE4":256,"NA":258},{"trials":245,"activeCount":75},[],{"trials":247,"activeCount":75},[],{"trials":249,"activeCount":75},[],{"trials":251,"activeCount":93,"soonestReadout":59},[252],{"nctId":57,"briefTitle":58,"status":83,"phases":253,"primaryCompletion":59,"completion":59,"start":85,"enrollment":86,"conditions":254,"interventions":255},[65],[88,89,15,90],[60,92,50,70],{"trials":257,"activeCount":75},[],{"trials":259,"activeCount":75},[],{"intervention":45,"totalTrials":93,"cells":261},{"EARLY_PHASE1":262,"PHASE1":264,"PHASE2":266,"PHASE3":268,"PHASE4":270,"NA":272},{"trials":263,"activeCount":75},[],{"trials":265,"activeCount":75},[],{"trials":267,"activeCount":75},[],{"trials":269,"activeCount":75},[],{"trials":271,"activeCount":75},[],{"trials":273,"activeCount":93,"soonestReadout":44},[274],{"nctId":42,"briefTitle":43,"status":83,"phases":275,"primaryCompletion":44,"completion":44,"start":276,"enrollment":162,"conditions":277,"interventions":278},[67],"2024-07-20",[15],[45,279],"Humalog",{"intervention":279,"totalTrials":93,"cells":281},{"EARLY_PHASE1":282,"PHASE1":284,"PHASE2":286,"PHASE3":288,"PHASE4":290,"NA":292},{"trials":283,"activeCount":75},[],{"trials":285,"activeCount":75},[],{"trials":287,"activeCount":75},[],{"trials":289,"activeCount":75},[],{"trials":291,"activeCount":75},[],{"trials":293,"activeCount":93,"soonestReadout":44},[294],{"nctId":42,"briefTitle":43,"status":83,"phases":295,"primaryCompletion":44,"completion":44,"start":276,"enrollment":162,"conditions":296,"interventions":297},[67],[15],[45,279],{"intervention":131,"totalTrials":9,"cells":299},{"EARLY_PHASE1":300,"PHASE1":302,"PHASE2":304,"PHASE3":310,"PHASE4":312,"NA":357},{"trials":301,"activeCount":75},[],{"trials":303,"activeCount":75},[],{"trials":305,"activeCount":75},[306],{"nctId":120,"briefTitle":121,"status":122,"phases":307,"primaryCompletion":124,"completion":125,"start":126,"enrollment":127,"conditions":308,"interventions":309},[64],[129,31],[108,131],{"trials":311,"activeCount":75},[],{"trials":313,"activeCount":75},[314,323,338,347],{"nctId":315,"briefTitle":316,"status":122,"phases":317,"primaryCompletion":318,"completion":318,"start":319,"enrollment":320,"conditions":321,"interventions":322},"NCT00118937","Effect of Metformin in Patients With Type-1 Diabetes With Inadequate Glycaemic Control by Insulin and Diet",[66],"2006-08","2003-12",100,[18],[131],{"nctId":324,"briefTitle":325,"status":122,"phases":326,"primaryCompletion":327,"completion":327,"start":328,"enrollment":329,"conditions":330,"interventions":333},"NCT00657943","The Copenhagen Insulin and Metformin Therapy Trial",[66],"2012-12","2008-04",415,[21,331,332],"Atherosclerosis","Arteriosclerosis",[334,335,336,337],"metformin","insulin detemir","insulin aspart + insulin aspart protamin","Insulin aspart",{"nctId":339,"briefTitle":340,"status":122,"phases":341,"completion":342,"start":343,"enrollment":320,"conditions":344,"interventions":345},"NCT00118950","Effect of Metformin Versus Repaglinide Treatment in Non-Obese Type 2 Diabetic Patients Uncontrolled by Diet",[66],"2003-03","2001-03",[27],[131,346],"Repaglinide",{"nctId":348,"briefTitle":349,"status":122,"phases":350,"primaryCompletion":351,"completion":351,"start":352,"enrollment":353,"conditions":354,"interventions":355},"NCT00118963","Effect of Repaglinide Versus Metformin Treatment in Non-Obese Patients With Type-2-Diabetes",[66],"2006-02","2003-01",102,[27],[131,356,346],"Insulin BIAsp30",{"trials":358,"activeCount":75},[],{"intervention":360,"totalTrials":361,"cells":362},"Liraglutide",3,{"EARLY_PHASE1":363,"PHASE1":365,"PHASE2":367,"PHASE3":369,"PHASE4":371,"NA":400},{"trials":364,"activeCount":75},[],{"trials":366,"activeCount":75},[],{"trials":368,"activeCount":75},[],{"trials":370,"activeCount":75},[],{"trials":372,"activeCount":75},[373,381,390],{"nctId":374,"briefTitle":375,"status":122,"phases":376,"primaryCompletion":377,"completion":377,"start":378,"enrollment":353,"conditions":379,"interventions":380},"NCT03449654","Effect of Liraglutide on Vascular Inflammation in Type-2 Diabetes",[66],"2019-08-16","2017-10-26",[27],[360],{"nctId":382,"briefTitle":383,"status":122,"phases":384,"primaryCompletion":385,"completion":385,"start":386,"enrollment":320,"conditions":387,"interventions":389},"NCT01612468","Liraglutide in Type 1 Diabetes",[66],"2015-02","2012-06",[18,388],"Overweight",[360],{"nctId":391,"briefTitle":392,"status":122,"phases":393,"primaryCompletion":394,"completion":394,"start":395,"enrollment":396,"conditions":397,"interventions":399},"NCT02545738","Antiproteinuric Effects of Liraglutide Treatment",[66],"2016-05","2015-04",32,[398],"Diabetic Kidney Disease",[360],{"trials":401,"activeCount":75},[],{"intervention":403,"totalTrials":71,"cells":404},"Spironolactone",{"EARLY_PHASE1":405,"PHASE1":407,"PHASE2":409,"PHASE3":411,"PHASE4":413,"NA":435},{"trials":406,"activeCount":75},[],{"trials":408,"activeCount":75},[],{"trials":410,"activeCount":75},[],{"trials":412,"activeCount":75},[],{"trials":414,"activeCount":75},[415,425],{"nctId":416,"briefTitle":417,"status":122,"phases":418,"completion":419,"start":420,"enrollment":421,"conditions":422,"interventions":424},"NCT00335413","Autoregulation of Glomerular Filtration Rate in Patients With Type 1 Diabetes During Spironolactone Therapy",[66],"2007-04","2006-06",17,[423],"Hypertension",[403],{"nctId":426,"briefTitle":427,"status":122,"phases":428,"completion":429,"start":430,"enrollment":431,"conditions":432,"interventions":434},"NCT00317954","Spironolactone in Diabetic Nephropathy",[66],"2005-07","2003-09",48,[433],"Diabetic Nephropathy",[403],{"trials":436,"activeCount":75},[],{"intervention":346,"totalTrials":71,"cells":438},{"EARLY_PHASE1":439,"PHASE1":441,"PHASE2":443,"PHASE3":445,"PHASE4":447,"NA":457},{"trials":440,"activeCount":75},[],{"trials":442,"activeCount":75},[],{"trials":444,"activeCount":75},[],{"trials":446,"activeCount":75},[],{"trials":448,"activeCount":75},[449,453],{"nctId":339,"briefTitle":340,"status":122,"phases":450,"completion":342,"start":343,"enrollment":320,"conditions":451,"interventions":452},[66],[27],[131,346],{"nctId":348,"briefTitle":349,"status":122,"phases":454,"primaryCompletion":351,"completion":351,"start":352,"enrollment":353,"conditions":455,"interventions":456},[66],[27],[131,356,346],{"trials":458,"activeCount":75},[],{"intervention":460,"totalTrials":93,"cells":461},"Forxiga",{"EARLY_PHASE1":462,"PHASE1":464,"PHASE2":466,"PHASE3":468,"PHASE4":470,"NA":484},{"trials":463,"activeCount":75},[],{"trials":465,"activeCount":75},[],{"trials":467,"activeCount":75},[],{"trials":469,"activeCount":75},[],{"trials":471,"activeCount":75},[472],{"nctId":473,"briefTitle":474,"status":122,"phases":475,"primaryCompletion":476,"completion":477,"start":478,"enrollment":479,"conditions":480,"interventions":483},"NCT04193566","Acute Effects of SGLT2 Inhibition on Renal Oxygenation and Autonomic Function in Type 1 Diabetes",[66],"2020-09-01","2021-01-01","2020-02-01",30,[208,212,481,15,482],"Mitochondrial Alteration","Autonomic Neuropathy, Diabetic",[460],{"trials":485,"activeCount":75},[],{"intervention":487,"totalTrials":93,"cells":488},"Spironolacton",{"EARLY_PHASE1":489,"PHASE1":491,"PHASE2":493,"PHASE3":495,"PHASE4":497,"NA":510},{"trials":490,"activeCount":75},[],{"trials":492,"activeCount":75},[],{"trials":494,"activeCount":75},[],{"trials":496,"activeCount":75},[],{"trials":498,"activeCount":75},[499],{"nctId":500,"briefTitle":501,"status":157,"phases":502,"primaryCompletion":503,"completion":503,"start":504,"enrollment":505,"conditions":506,"interventions":509},"NCT00843388","A Crossover Study With Hexalacton in Patients With Type 1 Diabetes and Microalbuminuria",[66],"2010-03","2009-03",20,[507,208,508],"Diabetes Mellitus","Blood Pressure",[487],{"trials":511,"activeCount":75},[],{"intervention":513,"totalTrials":93,"cells":514},"nisoldipine",{"EARLY_PHASE1":515,"PHASE1":517,"PHASE2":519,"PHASE3":521,"PHASE4":523,"NA":535},{"trials":516,"activeCount":75},[],{"trials":518,"activeCount":75},[],{"trials":520,"activeCount":75},[],{"trials":522,"activeCount":75},[],{"trials":524,"activeCount":75},[525],{"nctId":526,"briefTitle":527,"status":122,"phases":528,"completion":529,"start":530,"enrollment":531,"conditions":532,"interventions":533},"NCT00311870","Renoprotective Effect of Nisoldipine and Lisinopril in Type 1 Diabetic Nephropathy",[66],"1999-04","1993-03",52,[433],[513,534],"lisinopril",{"trials":536,"activeCount":75},[],{"intervention":538,"totalTrials":93,"cells":539},"irbesartan",{"EARLY_PHASE1":540,"PHASE1":542,"PHASE2":544,"PHASE3":546,"PHASE4":548,"NA":558},{"trials":541,"activeCount":75},[],{"trials":543,"activeCount":75},[],{"trials":545,"activeCount":75},[],{"trials":547,"activeCount":75},[],{"trials":549,"activeCount":75},[550],{"nctId":551,"briefTitle":552,"status":122,"phases":553,"completion":554,"start":430,"enrollment":531,"conditions":555,"interventions":557},"NCT00320879","Optimal Dose of Irbesartan for Renoprotection in Type 2 Diabetic Patients With Persistent Microalbuminuria",[66],"2004-11",[21,556],"Microalbuminuria",[538],{"trials":559,"activeCount":75},[],{"intervention":335,"totalTrials":93,"cells":561},{"EARLY_PHASE1":562,"PHASE1":564,"PHASE2":566,"PHASE3":568,"PHASE4":570,"NA":576},{"trials":563,"activeCount":75},[],{"trials":565,"activeCount":75},[],{"trials":567,"activeCount":75},[],{"trials":569,"activeCount":75},[],{"trials":571,"activeCount":75},[572],{"nctId":324,"briefTitle":325,"status":122,"phases":573,"primaryCompletion":327,"completion":327,"start":328,"enrollment":329,"conditions":574,"interventions":575},[66],[21,331,332],[334,335,336,337],{"trials":577,"activeCount":75},[],{"intervention":336,"totalTrials":93,"cells":579},{"EARLY_PHASE1":580,"PHASE1":582,"PHASE2":584,"PHASE3":586,"PHASE4":588,"NA":594},{"trials":581,"activeCount":75},[],{"trials":583,"activeCount":75},[],{"trials":585,"activeCount":75},[],{"trials":587,"activeCount":75},[],{"trials":589,"activeCount":75},[590],{"nctId":324,"briefTitle":325,"status":122,"phases":591,"primaryCompletion":327,"completion":327,"start":328,"enrollment":329,"conditions":592,"interventions":593},[66],[21,331,332],[334,335,336,337],{"trials":595,"activeCount":75},[],{"intervention":337,"totalTrials":93,"cells":597},{"EARLY_PHASE1":598,"PHASE1":600,"PHASE2":602,"PHASE3":604,"PHASE4":606,"NA":612},{"trials":599,"activeCount":75},[],{"trials":601,"activeCount":75},[],{"trials":603,"activeCount":75},[],{"trials":605,"activeCount":75},[],{"trials":607,"activeCount":75},[608],{"nctId":324,"briefTitle":325,"status":122,"phases":609,"primaryCompletion":327,"completion":327,"start":328,"enrollment":329,"conditions":610,"interventions":611},[66],[21,331,332],[334,335,336,337],{"trials":613,"activeCount":75},[],{"intervention":166,"totalTrials":93,"cells":615},{"EARLY_PHASE1":616,"PHASE1":618,"PHASE2":620,"PHASE3":622,"PHASE4":624,"NA":630},{"trials":617,"activeCount":75},[],{"trials":619,"activeCount":75},[],{"trials":621,"activeCount":75},[],{"trials":623,"activeCount":75},[],{"trials":625,"activeCount":75},[626],{"nctId":155,"briefTitle":156,"status":157,"phases":627,"primaryCompletion":159,"completion":160,"start":161,"enrollment":162,"conditions":628,"interventions":629},[66],[164],[40,166],{"trials":631,"activeCount":75},[],{"intervention":356,"totalTrials":93,"cells":633},{"EARLY_PHASE1":634,"PHASE1":636,"PHASE2":638,"PHASE3":640,"PHASE4":642,"NA":648},{"trials":635,"activeCount":75},[],{"trials":637,"activeCount":75},[],{"trials":639,"activeCount":75},[],{"trials":641,"activeCount":75},[],{"trials":643,"activeCount":75},[644],{"nctId":348,"briefTitle":349,"status":122,"phases":645,"primaryCompletion":351,"completion":351,"start":352,"enrollment":353,"conditions":646,"interventions":647},[66],[27],[131,356,346],{"trials":649,"activeCount":75},[],{"intervention":651,"totalTrials":93,"cells":652},"Linagliptin",{"EARLY_PHASE1":653,"PHASE1":655,"PHASE2":657,"PHASE3":659,"PHASE4":661,"NA":676},{"trials":654,"activeCount":75},[],{"trials":656,"activeCount":75},[],{"trials":658,"activeCount":75},[],{"trials":660,"activeCount":75},[],{"trials":662,"activeCount":75},[663],{"nctId":664,"briefTitle":665,"status":666,"phases":667,"primaryCompletion":668,"completion":668,"start":669,"enrollment":75,"conditions":670,"interventions":672},"NCT03504566","Rotation for Optimal Targeting of Albuminuria and Treatment Evaluation (ROTATE-2)","WITHDRAWN",[66],"2019-06-01","2017-11-15",[671],"Diabetic Nephropathy Type 2",[651,673,674,675],"Empagliflozin","Telmisartan","Sulodexide",{"trials":677,"activeCount":75},[],{"intervention":674,"totalTrials":93,"cells":679},{"EARLY_PHASE1":680,"PHASE1":682,"PHASE2":684,"PHASE3":686,"PHASE4":688,"NA":694},{"trials":681,"activeCount":75},[],{"trials":683,"activeCount":75},[],{"trials":685,"activeCount":75},[],{"trials":687,"activeCount":75},[],{"trials":689,"activeCount":75},[690],{"nctId":664,"briefTitle":665,"status":666,"phases":691,"primaryCompletion":668,"completion":668,"start":669,"enrollment":75,"conditions":692,"interventions":693},[66],[671],[651,673,674,675],{"trials":695,"activeCount":75},[],{"intervention":675,"totalTrials":93,"cells":697},{"EARLY_PHASE1":698,"PHASE1":700,"PHASE2":702,"PHASE3":704,"PHASE4":706,"NA":712},{"trials":699,"activeCount":75},[],{"trials":701,"activeCount":75},[],{"trials":703,"activeCount":75},[],{"trials":705,"activeCount":75},[],{"trials":707,"activeCount":75},[708],{"nctId":664,"briefTitle":665,"status":666,"phases":709,"primaryCompletion":668,"completion":668,"start":669,"enrollment":75,"conditions":710,"interventions":711},[66],[671],[651,673,674,675],{"trials":713,"activeCount":75},[],{"intervention":715,"totalTrials":93,"cells":716},"LOKELMA 5 GM Powder for Oral Suspension",{"EARLY_PHASE1":717,"PHASE1":719,"PHASE2":721,"PHASE3":723,"PHASE4":725,"NA":738},{"trials":718,"activeCount":75},[],{"trials":720,"activeCount":75},[],{"trials":722,"activeCount":75},[],{"trials":724,"activeCount":75},[],{"trials":726,"activeCount":75},[727],{"nctId":728,"briefTitle":729,"status":157,"phases":730,"primaryCompletion":731,"completion":732,"start":733,"enrollment":505,"conditions":734,"interventions":736},"NCT04063930","The Effect of Sodium Zirconium Cyclosilicate on Albuminuria in Patients With Type 2 Diabetes and Hyperkalemia",[66],"2020-12","2021-12","2019-10",[735],"Type 2 Diabetes Mellitus With Kidney Complications",[715,737],"Placebos",{"trials":739,"activeCount":75},[],{"intervention":737,"totalTrials":93,"cells":741},{"EARLY_PHASE1":742,"PHASE1":744,"PHASE2":746,"PHASE3":748,"PHASE4":750,"NA":756},{"trials":743,"activeCount":75},[],{"trials":745,"activeCount":75},[],{"trials":747,"activeCount":75},[],{"trials":749,"activeCount":75},[],{"trials":751,"activeCount":75},[752],{"nctId":728,"briefTitle":729,"status":157,"phases":753,"primaryCompletion":731,"completion":732,"start":733,"enrollment":505,"conditions":754,"interventions":755},[66],[735],[715,737],{"trials":757,"activeCount":75},[],{"intervention":759,"totalTrials":93,"cells":760},"anakinra",{"EARLY_PHASE1":761,"PHASE1":763,"PHASE2":765,"PHASE3":767,"PHASE4":778,"NA":780},{"trials":762,"activeCount":75},[],{"trials":764,"activeCount":75},[],{"trials":766,"activeCount":75},[],{"trials":768,"activeCount":75},[769],{"nctId":770,"briefTitle":771,"status":122,"phases":772,"primaryCompletion":773,"completion":386,"start":774,"enrollment":12,"conditions":775,"interventions":776},"NCT00711503","Anti-Interleukin-1 in Diabetes Action",[64,65],"2012-01","2009-01",[15],[759,777],"saline",{"trials":779,"activeCount":75},[],{"trials":781,"activeCount":75},[],{"intervention":783,"totalTrials":93,"cells":784},"Ezetimibe 10mg",{"EARLY_PHASE1":785,"PHASE1":787,"PHASE2":789,"PHASE3":791,"PHASE4":802,"NA":804},{"trials":786,"activeCount":75},[],{"trials":788,"activeCount":75},[],{"trials":790,"activeCount":75},[],{"trials":792,"activeCount":75},[793],{"nctId":794,"briefTitle":795,"status":157,"phases":796,"primaryCompletion":797,"completion":797,"start":798,"enrollment":799,"conditions":800,"interventions":801},"NCT04589351","Kidney Fat in Type 2 Diabetes and the Effects of Ezetimibe",[65],"2022-05","2020-10-01",60,[27,398],[783],{"trials":803,"activeCount":75},[],{"trials":805,"activeCount":75},[],{"intervention":807,"totalTrials":93,"cells":808},"Irbesartan treatment",{"EARLY_PHASE1":809,"PHASE1":811,"PHASE2":813,"PHASE3":815,"PHASE4":823,"NA":825},{"trials":810,"activeCount":75},[],{"trials":812,"activeCount":75},[],{"trials":814,"activeCount":75},[],{"trials":816,"activeCount":75},[817],{"nctId":818,"briefTitle":819,"status":122,"phases":820,"conditions":821,"interventions":822},"NCT00317915","Irbesartan in Type 2 Diabetes",[65],[21,556,423],[807],{"trials":824,"activeCount":75},[],{"trials":826,"activeCount":75},[],{"intervention":828,"totalTrials":71,"cells":829},"Dasiglucagon",{"EARLY_PHASE1":830,"PHASE1":832,"PHASE2":834,"PHASE3":854,"PHASE4":856,"NA":858},{"trials":831,"activeCount":75},[],{"trials":833,"activeCount":75},[],{"trials":835,"activeCount":75},[836,846],{"nctId":837,"briefTitle":838,"status":122,"phases":839,"primaryCompletion":840,"completion":841,"start":842,"enrollment":843,"conditions":844,"interventions":845},"NCT04764968","Pen-Administered Low-Dose Dasiglucagon for Prevention and Treatment of Hypoglycemia in People With Type 1 Diabetes",[64],"2021-12-30","2022-01-28","2021-04-27",24,[15,24],[828],{"nctId":847,"briefTitle":848,"status":122,"phases":849,"primaryCompletion":850,"completion":850,"start":851,"enrollment":505,"conditions":852,"interventions":853},"NCT04449692","Low-dose Dasiglucagon for Prevention of Insulin-Induced Hypoglycemia in People With Type 1 Diabetes",[64],"2021-01-04","2020-07-02",[15,24],[828],{"trials":855,"activeCount":75},[],{"trials":857,"activeCount":75},[],{"trials":859,"activeCount":75},[],{"intervention":861,"totalTrials":93,"cells":862},"mesenchymal stromal cells",{"EARLY_PHASE1":863,"PHASE1":865,"PHASE2":877,"PHASE3":879,"PHASE4":881,"NA":883},{"trials":864,"activeCount":75},[],{"trials":866,"activeCount":75},[867],{"nctId":868,"briefTitle":869,"status":870,"phases":871,"primaryCompletion":872,"completion":872,"start":873,"enrollment":71,"conditions":874,"interventions":876},"NCT03509870","Bone Marrow Derived Allogeneic Mesenchymal Stromal Cells to Non-healing Diabetic Foot Wounds","TERMINATED",[63],"2020-04-01","2018-06-01",[875],"Diabetic Foot Ulcer",[861],{"trials":878,"activeCount":75},[],{"trials":880,"activeCount":75},[],{"trials":882,"activeCount":75},[],{"trials":884,"activeCount":75},[],{"intervention":886,"totalTrials":93,"cells":887},"GLP-2",{"EARLY_PHASE1":888,"PHASE1":901,"PHASE2":903,"PHASE3":905,"PHASE4":907,"NA":909},{"trials":889,"activeCount":75},[890],{"nctId":891,"briefTitle":892,"status":122,"phases":893,"primaryCompletion":894,"completion":895,"start":896,"enrollment":897,"conditions":898,"interventions":900},"NCT03682172","Effect of Glucagon-like Peptide 2 on Gallbladder Motility After a Meal in Young, Healthy Male Subjects",[62],"2018-08-30","2020-07-01","2018-05-01",15,[899],"Effect of Glucagon-like Peptide 2 on Gallbladder Motility",[886,886],{"trials":902,"activeCount":75},[],{"trials":904,"activeCount":75},[],{"trials":906,"activeCount":75},[],{"trials":908,"activeCount":75},[],{"trials":910,"activeCount":75},[],{"intervention":912,"totalTrials":361,"cells":913},"Glucagon",{"EARLY_PHASE1":914,"PHASE1":916,"PHASE2":918,"PHASE3":920,"PHASE4":922,"NA":941},{"trials":915,"activeCount":75},[],{"trials":917,"activeCount":75},[],{"trials":919,"activeCount":75},[],{"trials":921,"activeCount":75},[],{"trials":923,"activeCount":75},[924,933],{"nctId":925,"briefTitle":926,"status":122,"phases":927,"primaryCompletion":928,"completion":928,"start":929,"enrollment":930,"conditions":931,"interventions":932},"NCT04053712","Dual-hormone Closed-loop Glucose Control in Type 1 Diabetes",[66],"2021-03-19","2019-07-16",13,[15,24],[912],{"nctId":934,"briefTitle":935,"status":122,"phases":936,"primaryCompletion":937,"completion":937,"start":938,"enrollment":22,"conditions":939,"interventions":940},"NCT04949867","Dual-Hormone Closed-Loop Glucose Control in Adolescents With Type 1 Diabetes",[66],"2022-04-26","2021-05-20",[15],[912],{"trials":942,"activeCount":75},[943],{"nctId":944,"briefTitle":945,"status":122,"phases":946,"primaryCompletion":947,"completion":947,"start":896,"enrollment":948,"conditions":949,"interventions":951},"NCT03526445","Hepatic Metabolic Changes in Response to Glucagon Infusion",[67],"2019-06-12",27,[34,950,507],"Total Pancreatectomy",[912,952],"Saline",{"intervention":952,"totalTrials":361,"cells":954},{"EARLY_PHASE1":955,"PHASE1":957,"PHASE2":959,"PHASE3":961,"PHASE4":967,"NA":969},{"trials":956,"activeCount":75},[],{"trials":958,"activeCount":75},[],{"trials":960,"activeCount":75},[],{"trials":962,"activeCount":75},[963],{"nctId":770,"briefTitle":771,"status":122,"phases":964,"primaryCompletion":773,"completion":386,"start":774,"enrollment":12,"conditions":965,"interventions":966},[64,65],[15],[759,777],{"trials":968,"activeCount":75},[],{"trials":970,"activeCount":75},[971,975],{"nctId":944,"briefTitle":945,"status":122,"phases":972,"primaryCompletion":947,"completion":947,"start":896,"enrollment":948,"conditions":973,"interventions":974},[67],[34,950,507],[912,952],{"nctId":976,"briefTitle":977,"status":122,"phases":978,"primaryCompletion":979,"completion":979,"start":980,"enrollment":16,"conditions":981,"interventions":982},"NCT05076292","Low-dose Glucagon for Prevention of Exercise-Induced Hypoglycemia in People With Type 1 Diabetes",[67],"2023-08-08","2021-11-23",[15,24],[983,952],"GlucaGen",{"intervention":983,"totalTrials":71,"cells":985},{"EARLY_PHASE1":986,"PHASE1":988,"PHASE2":990,"PHASE3":992,"PHASE4":994,"NA":996},{"trials":987,"activeCount":75},[],{"trials":989,"activeCount":75},[],{"trials":991,"activeCount":75},[],{"trials":993,"activeCount":75},[],{"trials":995,"activeCount":75},[],{"trials":997,"activeCount":75},[998,1006],{"nctId":999,"briefTitle":1000,"status":122,"phases":1001,"primaryCompletion":1002,"completion":1002,"start":1003,"enrollment":25,"conditions":1004,"interventions":1005},"NCT05379686","Glucagon and Advanced HCL System to Prevent Exercise-Induced Hypoglycaemia in People With Type 1 Diabetes",[67],"2024-05-13","2022-09-21",[15,24],[983],{"nctId":976,"briefTitle":977,"status":122,"phases":1007,"primaryCompletion":979,"completion":979,"start":980,"enrollment":16,"conditions":1008,"interventions":1009},[67],[15,24],[983,952],{"intervention":534,"totalTrials":71,"cells":1011},{"EARLY_PHASE1":1012,"PHASE1":1014,"PHASE2":1016,"PHASE3":1018,"PHASE4":1020,"NA":1026},{"trials":1013,"activeCount":75},[],{"trials":1015,"activeCount":75},[],{"trials":1017,"activeCount":75},[],{"trials":1019,"activeCount":75},[],{"trials":1021,"activeCount":75},[1022],{"nctId":526,"briefTitle":527,"status":122,"phases":1023,"completion":529,"start":530,"enrollment":531,"conditions":1024,"interventions":1025},[66],[433],[513,534],{"trials":1027,"activeCount":75},[1028],{"nctId":1029,"briefTitle":1030,"status":122,"phases":1031,"completion":1032,"start":1033,"enrollment":799,"conditions":1034,"interventions":1036},"NCT00118976","Maximal Dose of Angiotensin Converting Enzyme (ACE) Inhibitor for Treatment of Diabetic Kidney Disease",[67],"2006-09","2005-03",[1035,433],"Diabetes Mellitus, Type I",[1037],"Lisinopril",{"intervention":673,"totalTrials":71,"cells":1039},{"EARLY_PHASE1":1040,"PHASE1":1042,"PHASE2":1044,"PHASE3":1046,"PHASE4":1048,"NA":1054},{"trials":1041,"activeCount":75},[],{"trials":1043,"activeCount":75},[],{"trials":1045,"activeCount":75},[],{"trials":1047,"activeCount":75},[],{"trials":1049,"activeCount":75},[1050],{"nctId":664,"briefTitle":665,"status":666,"phases":1051,"primaryCompletion":668,"completion":668,"start":669,"enrollment":75,"conditions":1052,"interventions":1053},[66],[671],[651,673,674,675],{"trials":1055,"activeCount":75},[1056],{"nctId":1057,"briefTitle":1058,"status":122,"phases":1059,"primaryCompletion":1060,"completion":1060,"start":1061,"enrollment":1062,"conditions":1063,"interventions":1065},"NCT05417646","Impact of SGLT2 on Glucosuria in HNF1A-MODY",[67],"2023-06-14","2022-06-22",21,[1064,21],"Maturity-Onset Diabetes of the Young, Type 3",[673],{"intervention":1067,"totalTrials":93,"cells":1068},"Secretin",{"EARLY_PHASE1":1069,"PHASE1":1071,"PHASE2":1073,"PHASE3":1075,"PHASE4":1077,"NA":1079},{"trials":1070,"activeCount":75},[],{"trials":1072,"activeCount":75},[],{"trials":1074,"activeCount":75},[],{"trials":1076,"activeCount":75},[],{"trials":1078,"activeCount":75},[],{"trials":1080,"activeCount":75},[1081],{"nctId":1082,"briefTitle":1083,"status":122,"phases":1084,"primaryCompletion":1085,"completion":1085,"start":1086,"enrollment":1087,"conditions":1088,"interventions":1091},"NCT04613700","The Role of Secretin on the Energy Homeostasis",[67],"2020-09-29","2020-03-01",25,[31,1089,29,1090],"Metabolic Disease","Adiposity",[1067],{"intervention":1093,"totalTrials":93,"cells":1094},"Sevelamer",{"EARLY_PHASE1":1095,"PHASE1":1097,"PHASE2":1099,"PHASE3":1101,"PHASE4":1103,"NA":1105},{"trials":1096,"activeCount":75},[],{"trials":1098,"activeCount":75},[],{"trials":1100,"activeCount":75},[],{"trials":1102,"activeCount":75},[],{"trials":1104,"activeCount":75},[],{"trials":1106,"activeCount":75},[1107],{"nctId":1108,"briefTitle":1109,"status":122,"phases":1110,"primaryCompletion":1111,"completion":1112,"start":1113,"enrollment":421,"conditions":1114,"interventions":1116},"NCT03739268","GLP-1-mediated Gluco-metabolic Effects of Bile Acid Sequestration",[67],"2020-09-03","2021-09-01","2018-09-01",[1115],"Type 2 Diabetes Mellitus",[1093],{"intervention":1118,"totalTrials":93,"cells":1119},"glucose-dependent insulinotropic peptide",{"EARLY_PHASE1":1120,"PHASE1":1122,"PHASE2":1124,"PHASE3":1126,"PHASE4":1128,"NA":1130},{"trials":1121,"activeCount":75},[],{"trials":1123,"activeCount":75},[],{"trials":1125,"activeCount":75},[],{"trials":1127,"activeCount":75},[],{"trials":1129,"activeCount":75},[],{"trials":1131,"activeCount":75},[1132],{"nctId":1133,"briefTitle":1134,"status":122,"phases":1135,"primaryCompletion":1136,"completion":1136,"start":1137,"enrollment":1138,"conditions":1139,"interventions":1140},"NCT03556098","Glucose-dependent Insulinotropic Polypeptide as a Safeguard Against Hypoglycemia in Patients With Type 1 Diabetes",[67],"2020-02-11","2019-02-22",12,[18],[1118,1141,1142],"Glucose-Dependent Insulin-Releasing Hormone[3-30]","Saline Solution",{"intervention":1141,"totalTrials":93,"cells":1144},{"EARLY_PHASE1":1145,"PHASE1":1147,"PHASE2":1149,"PHASE3":1151,"PHASE4":1153,"NA":1155},{"trials":1146,"activeCount":75},[],{"trials":1148,"activeCount":75},[],{"trials":1150,"activeCount":75},[],{"trials":1152,"activeCount":75},[],{"trials":1154,"activeCount":75},[],{"trials":1156,"activeCount":75},[1157],{"nctId":1133,"briefTitle":1134,"status":122,"phases":1158,"primaryCompletion":1136,"completion":1136,"start":1137,"enrollment":1138,"conditions":1159,"interventions":1160},[67],[18],[1118,1141,1142],{"intervention":1142,"totalTrials":93,"cells":1162},{"EARLY_PHASE1":1163,"PHASE1":1165,"PHASE2":1167,"PHASE3":1169,"PHASE4":1171,"NA":1173},{"trials":1164,"activeCount":75},[],{"trials":1166,"activeCount":75},[],{"trials":1168,"activeCount":75},[],{"trials":1170,"activeCount":75},[],{"trials":1172,"activeCount":75},[],{"trials":1174,"activeCount":75},[1175],{"nctId":1133,"briefTitle":1134,"status":122,"phases":1176,"primaryCompletion":1136,"completion":1136,"start":1137,"enrollment":1138,"conditions":1177,"interventions":1178},[67],[18],[1118,1141,1142],{"intervention":1180,"totalTrials":93,"cells":1181},"GIP",{"EARLY_PHASE1":1182,"PHASE1":1184,"PHASE2":1186,"PHASE3":1188,"PHASE4":1190,"NA":1192},{"trials":1183,"activeCount":75},[],{"trials":1185,"activeCount":75},[],{"trials":1187,"activeCount":75},[],{"trials":1189,"activeCount":75},[],{"trials":1191,"activeCount":75},[],{"trials":1193,"activeCount":75},[1194],{"nctId":1195,"briefTitle":1196,"status":122,"phases":1197,"primaryCompletion":1198,"completion":1199,"start":668,"enrollment":505,"conditions":1200,"interventions":1201},"NCT03734718","The Role of Glucose-Dependent Insulinotropic Polypeptide in the Pathological Glucose Homeostasis Of Type 1 Diabetes",[67],"2019-12-12","2019-12-31",[18,24],[1180]]